Drug Profile
Research programme: tyrosine phophatase inhibitors - Apeiron Biologics
Alternative Names: APN 501; SHP-1inhLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator The Cleveland Clinic Foundation
- Developer Apeiron Biologics; Cleveland Clinic
- Class Small molecules
- Mechanism of Action SH2 domain-containing protein tyrosine phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 15 Mar 2011 Preclinical trials in Cancer in USA (PO)